- call +1-201-465-4211
- email sales@mrinsights.biz
Hormone Refractory Prostate Cancer (HRPCA) or Castrate-Resistant Prostate Cancer (CRPC), a type of prostate cancer that typically recurs after having hormonal therapy, is now under the spotlight in prostate cancer market. Due to the high unmet clinical need associated with limited survival periods, intensifying HRPCA prevalence and fast-emerging treatment modifications, the global HRPCA market is poised to witness an unprecedented growth.
Scope of the Report:
The global Hormone Refractory Prostate Cancer market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Hormone Refractory Prostate Cancer.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
This report studies the Hormone Refractory Prostate Cancer market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Hormone Refractory Prostate Cancer market by product type and applications/end industries.
Market Segment by Companies, this report covers
Astellas Inc
Sanofi S.A
Dendreon Corporation, Bayer AG
Johnson & Johnson
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Chemotherapy
Hormonal Therapy
Immunotherapy
Radiation Therapy
Surgery
Market Segment by Applications, can be divided into
Hospitals
Ambulatory Surgical Centers
Specialty Clinics
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Hormone Refractory Prostate Cancer Market Overview
1.1 Product Overview and Scope of Hormone Refractory Prostate Cancer
1.2 Classification of Hormone Refractory Prostate Cancer by Types
1.2.1 Global Hormone Refractory Prostate Cancer Revenue Comparison by Types (2017-2023)
1.2.2 Global Hormone Refractory Prostate Cancer Revenue Market Share by Types in 2017
1.2.3 Chemotherapy
1.2.4 Hormonal Therapy
1.2.5 Immunotherapy
1.2.6 Radiation Therapy
1.2.7 Surgery
1.3 Global Hormone Refractory Prostate Cancer Market by Application
1.3.1 Global Hormone Refractory Prostate Cancer Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Specialty Clinics
1.4 Global Hormone Refractory Prostate Cancer Market by Regions
1.4.1 Global Hormone Refractory Prostate Cancer Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Hormone Refractory Prostate Cancer Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Hormone Refractory Prostate Cancer Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Hormone Refractory Prostate Cancer Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Hormone Refractory Prostate Cancer Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Hormone Refractory Prostate Cancer Status and Prospect (2013-2023)
1.5 Global Market Size of Hormone Refractory Prostate Cancer (2013-2023)
2 Manufacturers Profiles
2.1 Astellas Inc
2.1.1 Business Overview
2.1.2 Hormone Refractory Prostate Cancer Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astellas Inc Hormone Refractory Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.2 Sanofi S.A
2.2.1 Business Overview
2.2.2 Hormone Refractory Prostate Cancer Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Sanofi S.A Hormone Refractory Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.3 Dendreon Corporation, Bayer AG
2.3.1 Business Overview
2.3.2 Hormone Refractory Prostate Cancer Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Hormone Refractory Prostate Cancer Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer Revenue, Gross Margin and Market Share (2016-2017)
3 Global Hormone Refractory Prostate Cancer Market Competition, by Players
3.1 Global Hormone Refractory Prostate Cancer Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Hormone Refractory Prostate Cancer Players Market Share
3.2.2 Top 10 Hormone Refractory Prostate Cancer Players Market Share
3.3 Market Competition Trend
4 Global Hormone Refractory Prostate Cancer Market Size by Regions
4.1 Global Hormone Refractory Prostate Cancer Revenue and Market Share by Regions
4.2 North America Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
4.3 Europe Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
4.5 South America Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
5 North America Hormone Refractory Prostate Cancer Revenue by Countries
5.1 North America Hormone Refractory Prostate Cancer Revenue by Countries (2013-2018)
5.2 USA Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
5.3 Canada Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
5.4 Mexico Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
6 Europe Hormone Refractory Prostate Cancer Revenue by Countries
6.1 Europe Hormone Refractory Prostate Cancer Revenue by Countries (2013-2018)
6.2 Germany Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
6.3 UK Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
6.4 France Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
6.5 Russia Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
6.6 Italy Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Hormone Refractory Prostate Cancer Revenue by Countries
7.1 Asia-Pacific Hormone Refractory Prostate Cancer Revenue by Countries (2013-2018)
7.2 China Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
7.3 Japan Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
7.4 Korea Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
7.5 India Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
8 South America Hormone Refractory Prostate Cancer Revenue by Countries
8.1 South America Hormone Refractory Prostate Cancer Revenue by Countries (2013-2018)
8.2 Brazil Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
8.3 Argentina Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
8.4 Colombia Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Hormone Refractory Prostate Cancer by Countries
9.1 Middle East and Africa Hormone Refractory Prostate Cancer Revenue by Countries (2013-2018)
9.2 Saudi Arabia Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
9.3 UAE Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
9.4 Egypt Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
9.5 Nigeria Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
9.6 South Africa Hormone Refractory Prostate Cancer Revenue and Growth Rate (2013-2018)
10 Global Hormone Refractory Prostate Cancer Market Segment by Type
10.1 Global Hormone Refractory Prostate Cancer Revenue and Market Share by Type (2013-2018)
10.2 Global Hormone Refractory Prostate Cancer Market Forecast by Type (2018-2023)
10.3 Chemotherapy Revenue Growth Rate (2013-2023)
10.4 Hormonal Therapy Revenue Growth Rate (2013-2023)
10.5 Immunotherapy Revenue Growth Rate (2013-2023)
10.6 Radiation Therapy Revenue Growth Rate (2013-2023)
10.7 Surgery Revenue Growth Rate (2013-2023)
11 Global Hormone Refractory Prostate Cancer Market Segment by Application
11.1 Global Hormone Refractory Prostate Cancer Revenue Market Share by Application (2013-2018)
11.2 Hormone Refractory Prostate Cancer Market Forecast by Application (2018-2023)
11.3 Hospitals Revenue Growth (2013-2018)
11.4 Ambulatory Surgical Centers Revenue Growth (2013-2018)
11.5 Specialty Clinics Revenue Growth (2013-2018)
12 Global Hormone Refractory Prostate Cancer Market Size Forecast (2018-2023)
12.1 Global Hormone Refractory Prostate Cancer Market Size Forecast (2018-2023)
12.2 Global Hormone Refractory Prostate Cancer Market Forecast by Regions (2018-2023)
12.3 North America Hormone Refractory Prostate Cancer Revenue Market Forecast (2018-2023)
12.4 Europe Hormone Refractory Prostate Cancer Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Hormone Refractory Prostate Cancer Revenue Market Forecast (2018-2023)
12.6 South America Hormone Refractory Prostate Cancer Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Hormone Refractory Prostate Cancer Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Hormone Refractory Prostate Cancer Picture
Table Product Specifications of Hormone Refractory Prostate Cancer
Table Global Hormone Refractory Prostate Cancer and Rev
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
